Exclusive Summary

• Covers full dosages (100mg-600mg), perfectly satisfying the dose titration guidelines for neuropathic pain and epilepsy, avoiding fragmented procurement for distributors.
• Listed as a WHO Essential Medicine and guideline-recommended first-line therapy, serving a massive global patient pool with exceptionally high inventory turnover and refill rates.
• Fully levering China's API-to-formulation economies of scale, it offers disruptive cost competitiveness, empowering overseas partners to secure high-volume public tenders.
• As a classic off-patent generic with fully mature market adoption, providing high-quality CTD dossiers ensures rapid regulatory approval and fast commercialization in target regions.